medical news
....For the majority of patients in the study, olaparib was at least their
third different cancer therapy. Based on the new data, the authors say
olaparib warrants further investigation in phase III trials.....
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.